Skip to main content

Gossamer Bio, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

GOSS$10.65+9.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

PART I. FINANCIAL INFORMATION
Item 1Condensed Consolidated Financial Statements (unaudited)4
Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 20254
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026 and 2025 (unaudited)5
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three Months ended March 31, 2026 and 2025 (unaudited)6
Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026 and 2025 (unaudited)7
Notes to Unaudited Condensed Consolidated Financial Statements8
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations27
Item 3Quantitative and Qualitative Disclosures About Market Risk35
Item 4Controls and Procedures35
PART II. OTHER INFORMATION
Item 1Legal Proceedings36
Item 1ARisk Factors36
Item 2Unregistered Sales of Equity Securities and Use of Proceeds36
Item 3Defaults Upon Senior Securities36
Item 4Mine Safety Disclosures36
Item 5Other Information36
Item 6Exhibits36
Exhibit Index37
Signatures38
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.